IBS Symptoms Raise IBD Healthcare Costs

Persistent gastrointestinal symptoms affect a significant number of patients with inflammatory bowel disease (IBD) who are technically in remission. A 2023 review from Cedars-Sinai Medical Center provides a critical framework for clinicians, arguing that automatically diagnosing these symptoms as irritable bowel syndrome (IBS) can lead to prolonged suffering and ineffective treatments.

The Problem of Persistent Symptoms in Controlled IBD

When a patient with Crohn’s disease or ulcerative colitis achieves endoscopic and biochemical remission, the expectation is a return to normal digestive function. For many, this is not the case. Recurrent abdominal pain, bloating, diarrhea, or constipation continue. Dr. Jane Lim and Dr. Ali Rezaie, authors of the review published in Digestive Diseases and Sciences, note that while an IBS diagnosis is frequently applied here, it is often a diagnostic placeholder. The symptoms may look like IBS, but the root cause is different.

Labeling these symptoms as IBS can set off a chain of negative outcomes. Patients may cycle through standard IBS therapies like dietary changes (e.g., low FODMAP) or gut-brain neuromodulators with little relief. This leads to repeated, sometimes invasive, testing, increased healthcare visits, and frustration. A more concerning risk, the authors warn, is the potential for clinicians to mistakenly assume the IBD is active and unnecessarily escalate treatments like steroids or biologics.

Beyond IBS: A Spectrum of Overlapping Conditions

The core argument of the review is that a wide range of specific conditions can mimic IBS in this population. These are not mere coincidences but often direct consequences of the underlying IBD or its treatment. The list is extensive and requires a detective’s approach.

Common organic mimics include bile acid diarrhea, which can occur after ileal resection in Crohn’s or due to impaired bile acid reabsorption. Small intestinal bacterial overgrowth (SIBO) is another frequent culprit, potentially driven by prior surgeries, intestinal strictures, or dysmotility. The review also highlights pancreatic exocrine insufficiency, carbohydrate intolerances (like lactose or fructose), and microscopic inflammation that evades standard endoscopic assessment.

Systemic disorders with gastrointestinal manifestations, such as thyroid dysfunction or connective tissue diseases, must also be considered. This complexity underscores why a one-size-fits-all IBS approach fails. As highlighted in our related article IBD vs IBS: Why the Right Diagnosis Matters for Your Gut Health, distinguishing between these entities is a fundamental clinical skill.

A Practical, Personalized Diagnostic Framework

Lim and Rezaie reject a blanket testing protocol. Instead, they advocate for a strategy driven by a meticulous patient history and physical examination. The goal is to identify clues that point toward a specific etiology before ordering tests.

For example, symptoms that worsen with high-fat meals might steer a clinician toward bile acid diarrhea or pancreatic insufficiency. A patient’s report of dramatic bloating and gas after certain fruits could indicate a carbohydrate intolerance. A history of multiple abdominal surgeries raises the index of suspicion for SIBO or adhesions. This symptom-pattern matching allows for targeted investigations, such as a SeHCAT scan for bile acids, a lactulose or glucose breath test for SIBO, or a fecal elastase test for pancreatic function.

This tailored method prevents a wasteful scattergun approach. It aligns with growing insights into personalized microbiome research, which seeks to move beyond generic treatments. The diagnostic process itself must be personalized.

Implications for Treatment and Patient Quality of Life

The most direct implication is that effective treatment depends on an accurate diagnosis. Managing bile acid diarrhea with a bile acid sequestrant, treating SIBO with a targeted antibiotic like rifaximin, or supplementing pancreatic enzymes can provide relief where IBS-directed therapies did not.

This approach has profound effects on patient well-being. Correctly identifying and treating the cause of symptoms reduces the physical burden and the psychological toll of an unexplained, chronic illness. It can prevent the anxiety and depression often associated with persistent gut symptoms, a link explored in research on the gut-brain axis in IBS. It also makes healthcare more efficient and cost-effective by reducing redundant consultations and tests.

Moving Forward: A Call for Clinical Vigilance

The review by Lim and Rezaie serves as a critical reminder for both clinicians and patients. For individuals with quiescent IBD who continue to struggle with IBS-like symptoms, “IBS” should not be the end of the diagnostic journey. It should be the starting point for a more detailed exploration.

This requires clinicians to maintain a high index of suspicion for overlapping conditions and to invest time in a comprehensive clinical evaluation. For patients, it means advocating for a thorough investigation when standard explanations and treatments don’t align with their experience. By shifting from a default IBS label to a targeted search for organic causes, the path to lasting symptom relief and improved quality of life becomes much clearer.

Source: Lim J, Rezaie A. Irritable Bowel Syndrome-Like Symptoms in Quiescent Inflammatory Bowel Disease: A Practical Approach to Diagnosis and Treatment of Organic Causes. Dig Dis Sci. 2023;68(11):4081-4097. doi:10.1007/s10620-023-08095-w. PMID: 37695549.